C
hronic kidney disease (CKD) is an important public health challenge. Approximately 10% to 15% of the adult population worldwide has CKD, and prevalence is increasing because of the epidemics of diabetes mellitus and obesity (1) . Chronic kidney disease causes illness and premature death. Nearly 50% of persons aged 70 years or older (1) and between 33% and 50% of persons with acute myocardial ischemia have CKD (2) . Even in early-stage CKD, the risk for premature cardiovascular disease is increased by 25% to 30% (3) and is more than 30-to 50-fold higher in persons with end-stage kidney disease (4) .
Antiplatelet agents are widely used to prevent cardiovascular events by inhibiting intravascular thrombosis. Antiplatelet drugs reduce vascular deaths by 15% and serious cardiovascular events by 20% in persons at high risk for a vascular event (5) . Extrapolating these benefits of antiplatelet therapy to persons with CKD is problematic because nonatherosclerotic conditions (cardiac failure, sudden cardiac death, and arrhythmia) are more common causes of cardiovascular events in persons with CKD than in the general population (5, 6) . The bleeding risk of antiplatelet agents may be greater (7) among persons with CKD because of impaired hemostasis (8) .
Treating complications of CKD imposes an important economic burden. Health costs of treating a person with CKD are nearly 3-fold higher than those for a person without CKD, and the cost of treating end-stage kidney disease is 10-fold higher (9, 10) . Together, increasing use of health resources, continued poor outcomes, and emergence of performance measures directed to the care of persons with CKD (11) necessitate careful evaluation of all health care interventions in this growing population. The aim of our study was to summarize the benefits and harms of anti-platelet agents in persons with CKD, focusing on cardiovascular events, mortality, and bleeding.
METHODS
We conducted a systematic review based on standard methods, including a published, peer-reviewed protocol (12) and reporting in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (13) .
Data Sources and Searches
We searched Embase from 1980 to November 2011, the Cochrane Central Register of Controlled Trials through Issue 4 of 2011, and the Cochrane Renal Group's specialized register through November 2011 without language restriction by using a search strategy designed by a specialist information manager (Appendix Table 1 , available at www.annals.org). The Cochrane Renal Group's register was populated by weekly Ovid MEDLINE AutoAlerts, quarterly searches from the Cochrane Central Register of Controlled Trials, and hand-searching. We contacted investigators to request unpublished data for persons who had CKD at baseline. We received and included additional data from these investigators for 3 trials that were not identified by our initial search (14 -16) . We screened the reference lists of retrieved publications, including a metaanalysis (5), for potentially eligible trials.
Study Selection
We included trials that compared antiplatelet agents with placebo, standard care, or no treatment in adults with CKD (as defined by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative criteria [17] ) or trials of broader populations for which data for participants with CKD could be disaggregated. Pediatric trials were excluded. We excluded 5 trials reporting follow-up shorter than 2 months (18 -22) because we wanted to focus on longer-term outcomes. Sensitivity analyses, including only trials with follow-up longer than 1 year, were conducted.
Data Extraction and Quality Assessment
Two or more independent authors screened the title and abstract of retrieved citations and reviewed the full text of potentially eligible citations to identify trials that fulfilled the inclusion criteria. For included trials, we extracted data on population characteristics; interventions; and outcomes, including fatal or nonfatal myocardial infarction or stroke, death (total and cause-specific), coronary artery revascularization, major or minor bleeding (Appendix Table 2 , available at www.annals.org) (6, 14 -16, 23-58) , end-stage kidney disease, all-cause hospitalization, and treatment withdrawal. Risk of bias was assessed according to standardized methods (59) .
Data Synthesis and Analysis
Relative risks (RRs) and 95% CIs were calculated from the numbers of events and participants at risk for events. When crude event rates were not provided, the reported risk ratio was extracted (27) . Relative risks and CIs were then summarized by using an exact bivariate randomeffects meta-analysis method following the approach proposed by Stijnen and colleagues (60) . Sensitivity analyses to check for robustness of our findings were performed with the "inverse of the sample size in the opposite treatment arm" (61) and the arcsine methods (62) . If exact bivariate random effects could not be used because crude event data were not available, we used a Bayesian meta-analysis following Greenland's "data equivalents" approach (63) .
We tested for heterogeneity of treatment effects between studies with the Cochran Q and I 2 test statistics (64) . Potential sources of heterogeneity in intervention effects were explored by prespecified subgroup analysis (type of antiplatelet regimen or stage of CKD [predialysis, dialysis, or kidney transplantation]) by reporting results of analyses when 4 or more studies were available for each subgroup. To assess potential bias from small study effects, we constructed funnel plots displaying the log RR on the horizontal axis and the SE of the log RR on the vertical axis. To evaluate the presence and extent of publication bias, we used the Egger regression test (65) .
We conducted sensitivity analyses, excluding shorter trials (Ͻ12 months) and those published only in internal drug company reports. We summarized the quality of evidence according to the Grading of Recommendations Assessment, Development, and Evaluation guidelines (66) . We conducted analyses by using SAS, version 9.1 (SAS Institute, Cary, North Carolina) ( 
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RESULTS

Description of Trials
Searching identified 1460 publications. Of these publications, 196 were reviewed in full text (Figure 1 ) and 40 eligible trials or patient subgroups of randomized trials (21 670 participants) were included (Appendix Table 3 , available at www.annals.org) (6, 14 -16, 23-58) . Thirty-six trials (20 942 participants) provided extractable data for inclusion in meta-analyses (6, 14 -16, 23-31, 34 -37, 39 -45, 47-58). We included unpublished subgroup data for persons with CKD that were provided by the investigators of 12 trials (11 732 participants) (6, 14 -16, 23-25, 28, 30, 37, 50, 58). Appendix Table 4 (available at www.annals .org) provides reasons for missing data in the meta-analyses.
Information for 4 trials (14, 43-45), including 2 internal company reports (44, 45), were available only in a previously published meta-analysis of antiplatelet agents (5). For 2 studies, the most complete information was provided in conference proceedings (32, 46), although neither of these trials provided extractable data for meta-analyses. Appendix Table 5 (available at www.annals.org) describes the sources of additional unpublished data.
Nine trials (9969 participants) provided information on antiplatelet treatment among persons with CKD who presented with an acute coronary syndrome or were scheduled to undergo coronary artery intervention and were considered at high risk for subsequent vessel closure (14 -16, 23-28) . All data for these trials were published (26, 27) or unpublished (14 -16, 23-25, 28 ) post hoc analyses for the subgroup of participants with CKD from larger trials. Trials provided data for glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, or tirofiban) (7 trials, 5471 participants) (14 -16, 23-26) or clopidogrel (2 trials, 4498 participants) (27, 28), and all involved coadministration of aspirin with (14, 15, (23) (24) (25) (26) or without (16, 27, 28) heparin as nonrandomized interventions. Median follow-up was 12 months.
The remaining 31 trials provided data for antiplatelet treatment among 11 701 persons with CKD who had stable or no cardiovascular disease. Twelve trials assessed the effects of antiplatelet agents on mortality, progression of kidney disease, or safety in 6970 patients with glomerulonephritis (4 trials, 119 participants) (29, 31, 33, 34) or diabetic nephropathy (6 trials, 2990 participants) (30, 32, 35-38) or who had an impaired glomerular filtration rate regardless of cause (2 trials, 3861 participants) (6, 58) . These trials generally involved administration of aspirin (6, 30, 36, 38) , dipyridamole (36), aspirin and dipyridamole (29, 31, 32, 36), or a thienopyridine (clopidogrel or ticlopidine) (34, 37). One trial involved administration of aspirin as a co-intervention (37). Median follow-up was 12 months.
Seventeen trials provided data for antiplatelet treatment in 4471 persons receiving or who would soon require dialysis (39 -54, 58). These trials involved administration of a range of antiplatelet agents (aspirin, dipyridamole, clopidogrel, sulfinpyrazone, ticlopidine, or picotamide), and 3 involved administration of additional antiplatelet agents or oral anticoagulation as nonrandomized cointerventions (39, 49, 52). Trials were generally of shorter duration (median, 6 months). Four trials administered antiplatelet treatment to 260 kidney transplant recipients (55-58).
Risk of Bias in Included Trials
Nine trials of acute coronary syndromes or percutaneous coronary intervention generally had low risk of bias, with a high proportion reporting adequate allocation concealment (78%), intention-to-treat analysis (89%), blinding of outcome assessors (100%), and freedom from selective outcome reporting (89%). However, all were post hoc analyses of trials of broader populations. In more than 75% of the remaining 31 trials, methods for random sequence generation, allocation concealment, blinding of outcome assessors, completeness to follow-up, or the risk for selective reporting or other biases were unclear or inadequate (Appendix Figure, available at www.annals.org). Figure 2 shows the overall results of all meta-analyses. The Table summarizes the quality of the available evidence (4, 66 -73) . Meta-analysis by using exact bivariate random effects is reported because sensitivity analyses suggested that the effect estimates were robust regardless of the statistical model used.
Meta-analysis
Effects on Vascular Events Among Patients With Acute Coronary Syndromes or Requiring Percutaneous Coronary Intervention
Fatal or Nonfatal Myocardial Infarction and Stroke
Low-quality evidence found that antiplatelet treatment plus standard care had little or no effect on myocardial infarction (7 (Figure 3 ).
All-Cause and Cardiovascular Mortality
Low-or very low-quality evidence found that antiplatelet therapy in addition to standard treatment had little or no effect on all-cause mortality ( All 9 trials (9863 participants) in persons with CKD and acute coronary syndromes or requiring percutaneous coronary intervention provided information on major and minor bleeding events (Figure 3) . Definitions of bleeding outcomes varied. Major bleeding was defined as an intracranial hemorrhage, a decrease in hemoglobin level of 50 g/L or more, or a decrease in hematocrit level of 15% or more in 7 trials (14 -16, 23-25, 28); a decrease in hemoglobin level of more than 40 g/L, bleeding necessitating transfusion of 2 units or more of blood, bleeding necessitating corrective surgery, or intracranial or retroperitoneal hemorrhage in 1 trial (26); or substantially disabling bleeding, intraocular bleeding leading to loss of vision, or bleeding necessitating transfusion of 2 units or more of blood in 1 trial (27). Minor bleeding included blood loss, a decrease in hemoglobin level of 30 g/L or more, or no observed blood loss with a decrease in hemoglobin level of 40 g/L or more (6 trials) (14, 16, 23, 25) ; interruption of study med- Summary estimates are provided by using random-effects meta-analysis. ACS ϭ acute coronary syndrome; PCI ϭ percutaneous coronary intervention. (14, 15, 24, 27, 28) . In the 5 trials that reported data for hemorrhagic stroke (14 -16, 24, 25) , treatment hazards of antiplatelet therapy were uncertain (4035 participants; RR, 1.08 [CI, 0.47 to 2.49]) (Figure 2 ).
Effects on Other Outcomes
Antiplatelet treatment had little or no effect on coronary artery revascularization (7 trials, 5265 participants; RR, 0.93 [CI, 0.84 to 1.04]) (Figure 3) . No data were available for treatment effects on all-cause hospi- No important publication bias ACS ϭ acute coronary syndrome; CKD ϭ chronic kidney disease; PCI ϭ percutaneous coronary intervention. * Quality assessed according to the Grading of Recommendations Assessment, Development, and Evaluation guidelines. Data obtained from reference 66. † Approximate absolute event rates of outcomes per year are derived from previously published data for myocardial infarction (68 -70) , all-cause mortality (4, 69 -72) , cardiovascular mortality (69 -72) , and bleeding (73) . Absolute numbers of persons with CKD who avoided events or had major bleeding were calculated from the risk estimate for the outcome (and associated 95% CI) obtained from a meta-analysis of placebo-controlled trials together with the absolute population risk estimated from previously published observational cohort studies. ‡ Effect considered imprecise when the CI includes possible benefit from both antiplatelet regimen and control approaches. § Relative risks and 95% CIs are based on random-effects models. Glycoprotein IIb/IIIa inhibitor or clopidogrel in addition to standard therapy vs. standard therapy alone. ¶ Antiplatelet agent vs. placebo, no treatment, or standard care.
talization, end-stage kidney disease, or withdrawal from treatment.
Effects on Clinical Outcomes Among Patients at Risk for or With Stable Cardiovascular Disease Fatal or Nonfatal Myocardial Infarction and Stroke
Moderate-quality evidence showed that antiplatelet therapy reduced myocardial infarction ( 
Effects on Adverse Events (Major and Minor Bleeding and Hemorrhagic Stroke)
Eighteen trials (10 230 participants) reported major bleeding events (6, 36, 37, 39 -45, 48, 49, 51-54, 57, 58), and 8 trials (7202 participants) reported minor bleeding events (6, 29, 36, 37, 40, 42, 52, 58) . No trials in this clinical setting reported data specifically for hemorrhagic stroke. Definitions of major and minor bleeding were generally not well-defined and were not centrally adjudicated with blinding to treatment allocation, with the exception of 2 trials (37, 58). Major bleeding included intracerebral or substantial hemodynamic compromise (37); gastrointestinal bleeding (39); hemarthrosis, nasal bleeding, shunt hemorrhage, and bleeding at injection site (42); confirmed retroperitoneal, intra-articular, intraocular, or intracranial bleeding or causing the hemoglobin level to decrease by 20 g/L or more and requiring hospital admission or transfusion (53); or hospital admission or death (58). Minor 
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Review Effects of Antiplatelet Therapy in Persons With CKD groups of trials based on stage of CKD or antiplatelet regimen were not possible.
Effects on Other Outcomes
Antiplatelet therapy had uncertain effects on end-stage kidney disease, hospitalization, and withdrawal from treatment (Figure 2) . No data were available for coronary artery revascularization in persons with CKD who have stable or no cardiovascular disease.
Small Study Effects and Publication Bias
No asymmetry was observed in the funnel plots for the outcomes of myocardial infarction, all-cause mortality, or major bleeding in trials involving persons at risk for or with stable cardiovascular disease or in those involving acute cardiovascular disease (Egger regression test, P Ͼ 0.10 for all). This finding suggests that unpublished studies did not cause bias of effect estimates.
DISCUSSION
To our knowledge, this meta-analysis provides the first comprehensive summary of the benefits and risks of antiplatelet treatment in persons with CKD. In general, evidence is of low or very-low quality, with considerable variation in trial duration; heterogeneity in the definitions and assessment of bleeding outcomes; reliance on subgroup data from major trials, particularly for antiplatelet treatment in acute cardiovascular disease; and substantial methodological limitations in data for adults with CKD and stable cardiovascular disease. Antiplatelet treatment (generally glycoprotein IIb/IIIa inhibitors) given in addition to standard care in persons with acute coronary syndromes or those undergoing percutaneous coronary revascularization who also have CKD has little or no effect on myocardial infarction, death, or coronary revascularization but increases major and minor bleeding. Evidence for an association between additional anti- 
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Review Effects of Antiplatelet Therapy in Persons With CKD platelet therapy and stroke and cardiovascular death in persons with CKD and who have acute coronary syndromes or who are undergoing percutaneous coronary intervention is scant. Antiplatelet regimens in persons with CKD who have or are at risk for cardiovascular disease reduce fatal or nonfatal myocardial infarction by approximately 33% but have uncertain effects on stroke or all-cause and cardiovascular mortality. Summary estimates for the effects of antiplatelet agents on major bleeding or hemorrhagic stroke are uncertain. Thienopyridines may increase mortality in persons with CKD and stable cardiovascular disease, although data are derived from subgroup analyses in few trials and are unreliable.
Overall, most trials of persons with CKD and stable or no cardiovascular disease have methodological or reporting limitations that reduce the reliability of the evidence. When absolute treatment effects are estimated, persons with acute coronary syndromes or who have undergone high-risk coronary intervention experience no reduction in myocardial infarction or subsequent need for revascularization with additional antiplatelet therapy. However, up to 2% of these persons may have serious bleeding. Twelve months of oral antiplatelet therapy may prevent myocardial infarction in 1% to 3% of persons at risk for myocardial infarction, but information about bleeding hazards and especially intracranial hemorrhage is of low or very low quality. Given the quality of the available evidence, specific trials evaluating antiplatelet agents in persons with CKD and coexisting acute or stable cardiovascular disease are required.
Outcome data for antiplatelet agents are scant in several important clinical settings. We currently have no data on persons receiving dialysis or kidney transplant recipients who have acute coronary syndromes or require coronary artery revascularization, and evidence for persons with earlier stages of CKD is entirely derived from post hoc analyses within larger trials. In addition, more and better evidence is required for long-term antiplatelet treatment in persons receiving dialysis or who have undergone kidney transplantation.
Evidence to support secondary prevention with lowcost antiplatelet drugs (such as aspirin) in persons with a recent occlusive myocardial event and coexisting CKD is not available, and extrapolating data from the general population may not be appropriate because the biology of arterial disease and causes of death in persons with CKD may confer a different risk-benefit tradeoff for therapy. As shown in the general population (74) tain value in persons with CKD because of the balance between reduced occlusive events (myocardial infarction) and the uncertain risk for major bleeding, including intracranial hemorrhage.
Although the values and preferences of patients with CKD are not well-understood (75) , it seems unlikely that many patients would accept the risk for major bleeding to reduce the risk for myocardial infarction without proven reductions in death or the need for coronary revascularization. The benefits and hazards of antiplatelet therapy to prevent cardiovascular events may be particularly important for patients receiving hemodialysis and dialysis-related anticoagulation who have impaired hemostasis (73) . However, these patients may also have greater absolute reductions in occlusive coronary events because of higher baseline risk (71) .
Considering the totality of current evidence, using antiplatelet and related agents to prevent cardiovascular events in people with CKD may be prudent only in clinical trials that can further define the role of these drugs. Recent prespecified subgroup data from the PLATO (Platelet Inhibition and Patient Outcomes) trial indicates that ticagrelor, an oral purinergic receptor inhibitor cleared by extrarenal mechanisms, reduces mortality and major cardiovascular events better than clopidogrel among persons with CKD and acute coronary syndromes (76) . This finding suggests that newer antiplatelet agents may potentially act as adjunctive therapy in persons with impaired kidney function. However, large placebo-controlled trials to assess the relative benefits and toxicity of these newer antiplatelet agents, in addition to standard care specifically in persons with CKD and acute cardiovascular disease, are needed.
An earlier collaborative meta-analysis (5) provided data for the effects of antiplatelet agents in patients receiving hemodialysis, but to our knowledge, outcome data for persons with earlier stages of CKD have not been previously summarized. In that previous meta-analysis (5) , antiplatelet therapy reduced major cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, and vascular death) by 41% in persons undergoing hemodialysis; however, CIs approached no effect, and the effects of treatment on individual components of the outcome were not reported. In that previous review (5), a meta-analysis that included only 46 events summarized bleeding risks with antiplatelet therapy in persons receiving hemodialysis, and estimates were-appropriately-considered unreliable.
We found a lack of a clear reduction in vascular deaths with antiplatelet treatment among persons with CKD; this finding is in contrast to findings observed in other populations at high risk for vascular events, including persons with a history of documented myocardial infarction and stroke (5). Our finding that antiplatelet agents reduce cardiovascular events in persons with CKD to a lesser extent than in other populations and have no certain effect on mortality in persons with CKD echoes similar treatment effects for statin therapy in persons with CKD (77). The competing mechanisms for cardiovascular disease in this population potentially explain this finding. Progressive kidney dysfunction is characterized by vascular stiffening and calcification, cardiomyopathy, hyperkalemia, and sudden cardiac death, in addition to occlusive vascular disease (78) .
We found that the proportional increased risk for serious bleeding from antiplatelet agents were 20% to 40%, which is somewhat smaller than that seen in patients with documented chronic or acute cardiovascular disease (60%) (5) . However, the substantially higher baseline risk for bleeding in persons with CKD (approximately 2.5% per year [73] compared with Ͻ1% in other at-risk populations [5] ) means that absolute bleeding risks with antiplatelet therapy might be at least doubled in persons with CKD.
It is also relevant to consider which specific bleeding complications are incurred by treatment when deciding whether the clinical benefits outweigh the potential risks of treatment in persons with CKD. Reversible hemorrhage from the gastrointestinal tract, skin, or dialysis access or surgical sites may be more acceptable treatment hazards than disabling bleeding into an eye, a joint, or the brain or bleeding requiring major surgery. However, insufficient data were available in the included trials to provide comprehensive information on specific types of bleeding caused by antiplatelet agents in this population and, consequently, on the relevant risk-benefit tradeoff needed to inform clinical decision making.
It is also important to remember that persons in the "real world" may have much higher risks for bleeding than trial participants. Therefore, the absolute numbers of persons with CKD affected by serious bleeding complications from antiplatelet treatment suggested in the Table may shift the balance toward excess harm.
Our meta-analysis quantifies the benefits and harms of antiplatelet agents in a large number of persons. However, it has limitations, largely because it relies on trial-level rather than individual-patient data. First, we could not assess whether the stage of kidney disease modified the effects of antiplatelet therapy. Second, definitions and assessments of bleeding were widely heterogeneous; therefore, estimates of hazards for specific bleeding events were less reliable. Third, overall trial duration varied greatly; in general, the longer-term effects (3 to 5 y) of antiplatelet treatment are uncertain.
Fourth, the amount of data available overall, and particularly that in persons with advanced CKD, was limited; as a result, insufficient power may explain some of the negative findings and highlights the need for trials of antiplatelet agents specifically targeting this population. In addition, reliance on data from post hoc analyses in larger trials may reduce the reliability of the summary findings (79) . This is particularly true for evidence in persons with CKD and acute cardiovascular disease, for whom available data provide hypothesis-generating, rather than confirmatory, evidence for antiplatelet treatment effects in this population-especially for adverse events. Finally, we were unable to determine the relative benefits of antiplatelet agents in primary prevention of cardiovascular disease (treating persons without clinically evident cardiovascular disease) compared with secondary prevention (treating persons with established cardiovascular disease) because too few trials provided data for participants in the primary prevention setting.
In conclusion, evidence for antiplatelet agents in persons with CKD and various cardiovascular diseases is of low quality. Glycoprotein IIb/IIIa inhibitors or clopidogrel given in addition to standard care have little or no effect on death, myocardial infarction, or coronary revascularization and may increase major bleeding in persons with CKD and acute coronary syndromes or those having high-risk coronary artery intervention. Antiplatelet agents reduce myocardial infarction in persons with CKD but have uncertain effects on stroke and mortality and may increase bleeding. Bleeding hazards and lack of clear efficacy in reducing cardiovascular morbidity and mortality need to be acknowledged when patients with CKD are being counseled about acute or long-term antiplatelet therapy. 
